Drugs / Baitouweng Tang
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06421818 | May 2024 → Dec 2026 expected | ulcerative colitis | The Second Hospital of Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Baitouweng Tang | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06421818 ↗ |
| Action | Inhibit | “BTW significantly suppressed mTORC1 activity in the colon tissues of UC mice.” PMID 36581160 ↗ Dec 2022 |
| Route | Other | “administered through the colonic TET” NCT06421818 ↗ |